Strålin Kristoffer, Olcén Per, Törnqvist Eva, Holmberg Hans
Department of Infectious Diseases, Orebro University Hospital, Orebro, Sweden.
Scand J Infect Dis. 2010 Jul;42(6-7):426-34. doi: 10.3109/00365540903552353.
According to the recommendations of the Swedish Community-Acquired Pneumonia (CAP) guidelines, the selection of empirical antibiotic therapy should be based on the CRB-65 rule. The guidelines recommend empirical therapy directed predominantly against Streptococcus pneumoniae for patients with low CRB-65 scores and broad-spectrum therapy for patients with high CRB-65 scores. In order to study the utility of the recommendations, we analyzed the data from an aetiological study previously performed on 235 hospitalized adult CAP patients at our medical centre. A definite, probable, or possible bacterial aetiology was noted in 194 cases (83%), including 112 cases (48%) with S. pneumoniae aetiology. The following frequencies of definite-probable aetiologies were noted in the patients with CRB-65 score 0-1 (n=155) and CRB-65 score 2-4 (n=80): S. pneumoniae 30% and 35%, Haemophilus influenzae 6.5% and 14% (p=0.063), Mycoplasma pneumoniae 15% and 5.0% (p=0.019), Chlamydophila species 2.6% and 1.2%, Legionella pneumophila 1.9% and 0%, and Staphylococcus aureus 1.3% and 1.2%, respectively. The high frequency of S. pneumoniae in the study supports the recommendations to predominantly cover this bacterium in the empirical therapy of patients with low CRB-65 scores. In the case of treatment failure in these patients, the study indicates that coverage against M. pneumoniae and H. influenzae should be considered.
根据瑞典社区获得性肺炎(CAP)指南的建议,经验性抗生素治疗的选择应基于CRB-65规则。该指南建议,对于CRB-65评分低的患者,经验性治疗主要针对肺炎链球菌;对于CRB-65评分高的患者,则采用广谱治疗。为了研究这些建议的实用性,我们分析了此前在我们医疗中心对235例住院成年CAP患者进行的一项病因学研究的数据。在194例(83%)病例中发现了明确、很可能或可能的细菌病因,其中112例(48%)为肺炎链球菌病因。在CRB-65评分为0-1(n=155)和CRB-65评分为2-4(n=80)的患者中,明确-很可能病因的出现频率如下:肺炎链球菌分别为30%和35%,流感嗜血杆菌分别为6.5%和14%(p=0.063),肺炎支原体分别为15%和5.0%(p=0.019),嗜衣原体属分别为2.6%和1.2%,嗜肺军团菌分别为1.9%和0%,金黄色葡萄球菌分别为1.3%和1.2%。该研究中肺炎链球菌的高出现频率支持了在CRB-65评分低的患者经验性治疗中主要覆盖该细菌的建议。对于这些患者治疗失败的情况,该研究表明应考虑覆盖肺炎支原体和流感嗜血杆菌。